We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.82 | -1.07% | 75.53 | 75.34 | 75.45 | 18,658 | 10:59:09 |
From May 2022 to May 2024
By Denny Jacob
Drugmaker Merck & Co. and pharmaceutical company AstraZeneca PLC on Thursday said the Food and Drug Administration will extend the date for lynparza's pending supplement new drug application.
The companies said the extension is to provide more time to fully review the submission.
The application is for lynparza in combination with abiraterone and prednisone or prednisolone as a treatment for adults with metastatic castration-resistant prostate cancer, Merck and AstraZeneca said.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 15, 2022 07:15 ET (12:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
